Compare Delta Air Lines, Inc. (DAL) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Delta Air Lines, Inc. vs Illumina, Inc. — how do they compare? Delta Air Lines, Inc. trades at $89.86 (market cap $59.46B), while Illumina, Inc. trades at $191.16 (market cap $29.12B). The key difference: Delta Air Lines, Inc. is far larger — about 2× Illumina, Inc.'s market cap, and Delta Air Lines, Inc. pays a 0.86% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| DAL | ILMN | |
|---|---|---|
Market Cap | $59.46B | $29.12B |
Sector | Industrials | Health |
52-Week High | $93.66 | $205.10 |
52-Week Low | $55.65 | $91.00 |
Enterprise Value | $74.77B | $30.48B |
Dividend Yield | 0.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Delta Air Lines (DAL) trades at $89.21, down 2.33% on the day, amid strong fundamental performance with three consecutive quarterly earnings beats. The stock maintains attractive valuation metrics including a P/E of 14.99 and P/S of 0.87, while showing robust profitability with 20.12% ROE. Technical indicators suggest a bullish trend with current price near key support at $89. Recent corporate developments include dividend payments and strong cash flow generation of $1.08 billion in 2025.
DAL presents a compelling investment case with strong analyst support (82% buy ratings) and a $108.27 consensus price target implying 21% upside. The airline benefits from premium travel demand and lucrative loyalty partnerships, though faces headwinds from fuel cost volatility and competitive pressures. Earnings momentum remains positive with Q3 2026 expectations of $2.19 EPS.
Illumina (ILMN) trades at $191.79, up 2.04% today, with a neutral technical signal and strong fundamental recovery. The stock shows bullish moving averages but faces resistance near $194. Recent earnings beats and a return to profitability in 2025, with $850M net income, highlight operational turnaround. Revenue remains stable around $4.3B, supported by robust gross margins of 66.38%.
Outlook is positive with analyst consensus Buy rating and $201.58 price target, though high P/E of 35.98 poses valuation risk. Key opportunities include sequencing demand and AI partnerships, while risks involve debt levels and competitive pressures. Institutional activity is mixed, with some funds increasing stakes amid earnings momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
